Reimbursement Contracts: Application of Civil Law Mechanisms under Pandemic Restrictions

Keywords: reimbursement, reimbursement contract, pandemic, civil law mechanism, reduction of variability, compensation for expenses

Abstract

The article contextualizes and assesses the peculiarities of using the mechanism of civil law reimbursement of medical expenses in the context of the global spread of acute respiratory infection COVID-19 caused by coronavirus SARS-CoV-2, as well as the theoretical possibility of such coverage of financial costs and revenues through the enforcement of reimbursement contracts, by analogy with the currently widespread state program «Affordable Medicines of Ukraine». The author analyses the achievements of many domestic and foreign researchers who have covered various aspects of reimbursement in their writings, including the extrapolation algorithms of such traditional institutions of civil law as the fulfilment of obligations for the third parties, compensation, etc. For the completeness of the scientific search, the article also contains an analysis of statistical indicators of the effectiveness of reimbursement contracts in our country, based on information from open official sources of the National Health Service of Ukraine. As a result of the comparison, the author concluded that the well-thought-out organization of high-quality medical care, followed by reimbursement of the full or partial cost of services received or medicines purchased under reimbursement agreements allows to comprehensively and effectively solve most problems in this area in such a way as to protect the interests of patients, doctors, and pharmaceutical companies as the key participants in such legal relations. It is also emphasized that the system of legal regulation and medical provision of access to medicines and procedures in most developed countries is considered as an integral part of public administration, the need to improve which is always an urgent challenge for every law enforcement, especially in the context of the global spread of acute respiratory infection COVID-19 caused by the coronavirus SARS-CoV-2. Particular attention is paid to the fact that the well-thought-out organization of quality medical care, followed by reimbursement of the full or partial cost of services received or drugs purchased in the context of reimbursement agreements allows comprehensive and effective solutions to most problems in this area to protect the interests of patients, doctors and pharmaceutical companies as key participants in such legal relations.

References

Poltavtseva, A. S. (2014) Reimbursatsiia v systemi rehuliuiuchoho vplyvu derzhavy na farmatsevtychnomu rynku: postanovka pytannia. Pravo i suspilstvo, 3, 218–221.

Deshko, L. (2007) Derzhavne rehuliuvannia tsinoutvorennia na likarski zasoby v krainakh Yevropeiskoho spivtovarystva ta inshykh krainakh. Pipryiemnytstvo, hospodarstvo i pravo, 12, 88–91.

Medicines Reimbursement policies in Europe (2018). Retrieved from World Health Organization: https://bit.ly/2NmYNpl.

Pro vporiadkuvannia bezoplatnoho ta pilhovoho vidpusku likarskykh zasobiv za retseptamy likariv u razi ambulatornoho likuvannia okremykh hrup naselennia ta za pevnymy katehoriiamy zakhvoriuvan. Postanova Kabinetu Ministriv Ukrainy vid 17.08.1998 r. № 1303. (N.d.) Retrieved from Verkhovna Rada Ukrainy. Zakonodavstvo Ukrainy: http://bit.ly/3lryPNV.

Soldatenko, O. (2010) Reimbursatsiia yak odyn iz vydiv finansuvannia vydatkiv na okhoronu zdorovia. Viche, 8, 19–20.

Deiaki pytannia shchodo dohovoriv pro reimbursatsiiu. Postanova Kabinetu Ministriv Ukrainy vid 27.02.2020 r. № 136. (N.d.) Retrieved from Verkhovna Rada Ukrainy. Zakonodavstvo Ukrainy: http://bit.ly/30K5eG3.

Deiaki pytannia reimbursatsii likarskykh zasobiv. Postanova Kabinetu Ministriv Ukrainy vid 27.02.2019 r. № 135. (N.d.) Retrieved from Verkhovna Rada Ukrainy. Zakonodavstvo Ukrainy: http://bit.ly/30PtPJz.

Pro zatverdzhennia formy Reiestru likarskykh zasobiv, yaki pidliahaiut reimbursatsii. Zatv. nakazom Ministerstva okhorony zdorovia Ukrainy vid 22.03.2019 r. № 635. (N.d.) Retrieved from Verkhovna Rada Ukrainy. Zakonodavstvo Ukrainy: http://bit.ly/38GrWmU.

Zhuravleva, L. V., Smirnov, I. I., Pylev, D. I. (2020) Sovremennye tehnologii v kontrole: vzgljad klinicista na problemu i perspektivy. Lіki Ukraїni, 4 (240), 40–43.

Rockwell, K. L., Gilroy, A. S. (2020) Incorporating telemedicine as part of COVID-19 outbreak response systems. The American Journal of Managed Care, 26 (4), 17–18. https://doi.org/10.37765/ajmc.2020.42784.

Hemminki, E., Bomann-Larsen, P. (1981) Drug Reimbursement in Four Nordic Countries. Scandinavian Journal of Social Medicine, 9 (1), 1–10. https://doi.org/10.1177/140349488100900101.

Kircher, S. M., Mulcahy, M., Kalyan, A., Weldon, C. B., Trosman, J., Benson, J. (2020) Telemedicine in Oncology and Reimbursement Policy During COVID-19 and Beyond. JNCCN, 1–7.

Pashkov, V. M. (2012) Osoblyvosti tsinovoi polityky derzhavy shchodo produktsii farmatsevtychnoho vyrobnytstva. Visnyk akademii pravovykh nauk Ukrainy, 3 (70), 146–158.

Bielichenko, A. V. (2010) Derzhavne rehuliuvannia zabezpechennia naselennia likarskymy zasobamy : avtoref. dys. … kand. derzh. upr.. Kharkiv.

Pro vnesennia zminy do punktu 9 Poriadku ukladennia, zminy ta prypynennia dohovoru pro reimbursatsiiu. Postanova Kabinetu Ministriv Ukrainy vid 25.11.2020 r. № 1154. (N.d.) Retrieved from Verkhovna Rada Ukrainy. Zakonodavstvo Ukrainy: http://bit.ly/30L7fS6.

Kostiuk, I. A. (2019) Analiz dynamiky asortymentu likarskykh zasobiv dlia farmakoterapii bronkhialnoi astmy u prohrami «Dostupni liky». Farmatsevtychnyi zhurnal, 74 (5), 12–20.

Kim, Y. W., Roberts, A., Brown, T. (2016) Impact of Product Characteristics and Market Conditions on Contract Type: Use of Fixed-Price Versus Cost-Reimbursement Contracts in the U.S. Department of Defense. Calhoun: The NPS Institutional Archive, 39 (4), 783–813. https://doi.org/10.1080/15309576.2015.1137765.

Garfield S. Advancing Access to Personalized Medicine: A Comparative Assessment of European Reimbursement System. (N.d.) Retrieved from Personalized Medicine Coalition: https://bit.ly/2PZaKlQ.

Morgan S., Daw J., Thomson P. International best practices for negotiating ‘reimbursement contracts with price rebates from pharmaceutical companies. Health Affairs. 2013, Apr 32 (4). Pp. 771–777. https://doi.org/10.1377/hlthaff.2012.1268.

Khatoon, A. A (2020) Blockchain-Based Smart Contract System for Healthcare Management: the case of reimbursement banks. Galway Electronics, 9 (94) (1), 1–24. https://doi.org/10.3390/electronics9010094.

Hetalo, O. V., Kratenko, A. O. (2019) Analiz sotsialno-ekonomichnoho stanu systemy reimbursatsii vartosti likarskykh zasobiv za kordonom. Scientific journal «ΛΌHOΣ. The art of scientific mind, 2, 62–64.

Acquatella A. (2020) Optimal Reimbursement Contracts for Provider Administered Treatments.

Published
2020-12-31
Section
COVID-19